

THURSDAY, 19 MAY 2016

08.30 – 10.45 Session 1

08.30 Emerging insights into the immunopathophysiology of MS
Roland Liblau (Toulouse, FR)

09.15 Brain of MS patient: MRI, PET, clinical manifestation
Igor Stolyarov (St. Petersburg, RU)

10.00 Cognitive impairment in MS
Maria Pia Amato (Florence, IT)

10.45 – 11.15 Coffee Break

11.15 - 13.30 Session 2

11.15 Modern diagnostic work-up of patients suspected of MS and clinical phenotypes
Tobias Derfus (Basel, CH)

12.00 Mechanism of action of therapeutic monoclonal antibodies
Alexey Boyko (Moscow, RU)

12.45 Mechanism of action of oral therapies
Roland Liblau (Toulouse, FR)

FRIDAY, 20 MAY 2016

08.30 – 10.45 Workshop 1: When and how to start therapy. Should all CIS patients and RIS patients be treated?

Finn Sellebjerg (Copenhagen, DK)

Workshop 2: Escalating or switching therapy. Treat to NEDA 2, 3 or 4?

Per Soelberg Sørensen (Copenhagen, DK)

Workshop 3: Monitoring therapy and adherence to therapy

Tobias Derfuss (Basel, CH)

Each workshop will take place 08.30-09.15; 09.15-10.00; 10.00-10.45

10.45 – 11.15 Coffee Break

11.15 – 13.30 Session 3

11.15 Risk stratification and mitigation considerations with new MS therapies
Per Soelberg Sørensen (Copenhagen, DK)

12.00 Place of haematological and mesenchymal stem cell treatment in MS
Nikolaos Grigoriadis (Thessaloniki, GR)

12.45 Current treatment algorithm and future changes
Xavier Montalban (Barcelona, ES)